Yongsu B. Zhen

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100050, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

A Human β-Defensin-Based Recombinant Protein DF2-HSA Ameliorates Cytokine Storm.

A Human β-Defensin-Based Recombinant Protein DF2-HSA Ameliorates Cytokine Storm.

Journal: Cells

Published: December 29, 2025

The triple combination DBDx alleviates cytokine storm and related lung injury.

The triple combination DBDx alleviates cytokine storm and related lung injury.

Journal: International immunopharmacology

Published: May 05, 2024

A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

Journal: Drug delivery

Published: April 13, 2022

Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression.

Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression.

Journal: Biochemical pharmacology

Published: August 23, 2021

Advances and challenges in the treatment of esophageal cancer.

Advances and challenges in the treatment of esophageal cancer.

Journal: Acta pharmaceutica Sinica. B

Published: October 12, 2020

An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.

An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.

Journal: Oncology reports

Published: August 04, 2019

An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma.

An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma.

Journal: Frontiers in oncology

Published: June 24, 2019

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Journal: Cancer letters

Published: November 29, 2018

A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.

A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.

Journal: Molecular pharmaceutics

Published: May 15, 2018

A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas.

A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas.

Journal: Molecular oncology

Published: November 01, 2017

A new compound of thiophenylated pyridazinone IMB5043 showing potent antitumor efficacy through ATM-Chk2 pathway.

A new compound of thiophenylated pyridazinone IMB5043 showing potent antitumor efficacy through ATM-Chk2 pathway.

Journal: PloS one

Published: October 26, 2017

An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.

An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.

Journal: Journal of Cancer

Published: August 08, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026